Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

74 results

Filters applied: . Clear all
Page 1
Long-term outcomes of definitive radiation with volumetric modulated arc therapy and concurrent chemotherapy for squamous cell carcinoma of the anus in a regional Australian cancer centre.
Hsieh MT, Shakespeare TP, Winkley L, Goonetilleke D, Yap SZL, Tahir ARM. Hsieh MT, et al. Among authors: yap szl. J Med Imaging Radiat Oncol. 2024 Apr;68(3):325-332. doi: 10.1111/1754-9485.13630. Epub 2024 Mar 7. J Med Imaging Radiat Oncol. 2024. PMID: 38450897
Volumetric arc therapy (VMAT) is a highly conformal radiation therapy technique that has been implemented to reduce toxicity for these patients. However, there are few reports evaluating the long-term outcomes of VMAT. Thus, we evaluated the survival and toxicity outcomes …
Volumetric arc therapy (VMAT) is a highly conformal radiation therapy technique that has been implemented to reduce toxicity for these patie …
Real-World Experience of Carglumic Acid for Methylmalonic and Propionic Acidurias: An Interim Analysis of the Multicentre Observational PROTECT Study.
Yap S, Lamireau D, Feillet F, Ruiz Gomez A, Davison J, Tangeraas T, Giordano V. Yap S, et al. Drugs R D. 2024 Mar;24(1):69-80. doi: 10.1007/s40268-023-00449-z. Epub 2024 Jan 10. Drugs R D. 2024. PMID: 38198106 Free PMC article.
Carglumic acid, a synthetic analogue of N-acetylglutamate, decreases ammonia levels by restoring the functioning of the urea cycle. However, there are limited data available on the long-term safety and effectiveness of carglumic acid. Here, we present an interim analysis o …
Carglumic acid, a synthetic analogue of N-acetylglutamate, decreases ammonia levels by restoring the functioning of the urea cycle. However, …
Outcomes in Dutch DPP6 risk haplotype for familial idiopathic ventricular fibrillation: a focused update.
Bergeman AT, Hoeksema WF, van der Ree MH, Boersma LVA, Yap SC, Verheul LM, Hassink RJ, van der Crabben SN, Volders PGA, van der Werf C, Wilde AAM, Postema PG; European Reference Network for rare, low prevalence and complex diseases of the heart: ERN GUARD-Heart. Bergeman AT, et al. Among authors: yap sc. Neth Heart J. 2023 Aug;31(7-8):309-314. doi: 10.1007/s12471-023-01792-1. Epub 2023 Jul 27. Neth Heart J. 2023. PMID: 37498467 Free PMC article.
BACKGROUND: The genetic risk haplotype DPP6 has been linked to familial idiopathic ventricular fibrillation (IVF), but the associated long-term outcomes are unknown. METHODS: DPP6 risk haplotype-positive family members (DPP6 cases) and their risk haplotype-negative relativ …
BACKGROUND: The genetic risk haplotype DPP6 has been linked to familial idiopathic ventricular fibrillation (IVF), but the associated long- …
PSMA-PET-guided dose-escalated volumetric arc therapy for newly diagnosed lymph node-positive prostate cancer: 5 Year outcomes following the FROGG and EviQ node-positive guidelines.
Yap SZL, Armstrong S, Aherne N, Shakespeare TP. Yap SZL, et al. J Med Imaging Radiat Oncol. 2023 Jun;67(4):456-462. doi: 10.1111/1754-9485.13534. Epub 2023 Apr 26. J Med Imaging Radiat Oncol. 2023. PMID: 37186452
CONCLUSION: Outcomes following FROGG guidelines and EviQ are promising, with high long-term disease control and low toxicity. Contouring guidelines require modification due to the high rate of PET-positive nodes demonstrated beyond recommended coverage....
CONCLUSION: Outcomes following FROGG guidelines and EviQ are promising, with high long-term disease control and low toxicity. Contour …
Long-Term Outcome of ICD Therapy in Patients With Noncompaction Cardiomyopathy Compared With DCM and HCM.
Kaya E, Otten M, Theuns DAMJ, Veen K, Yap SC, Schinkel AFL, Constantinescu AA, Michels M, Manintveld OC, Szili-Torok T, Caliskan K. Kaya E, et al. Among authors: yap sc. JACC Clin Electrophysiol. 2023 Aug;9(8 Pt 1):1368-1378. doi: 10.1016/j.jacep.2023.01.011. Epub 2023 Mar 22. JACC Clin Electrophysiol. 2023. PMID: 37141904
BACKGROUND: Implantable cardioverter-defibrillators (ICDs) are frequently used for primary and secondary prevention in patients with cardiomyopathies due to different etiologies. However, long-term outcome studies in patients with noncompaction cardiomyopathy (NCCM) are sc …
BACKGROUND: Implantable cardioverter-defibrillators (ICDs) are frequently used for primary and secondary prevention in patients with cardiom …
The performance of dipole charge density mapping integrated with robotic magnetic navigation in the treatment of atrial tachycardias.
Gagyi RB, Yap SC, Noten AME, Wijchers S, Szili-Torok T. Gagyi RB, et al. Among authors: yap sc. J Interv Card Electrophysiol. 2023 Dec;66(9):2103-2111. doi: 10.1007/s10840-023-01552-6. Epub 2023 Apr 20. J Interv Card Electrophysiol. 2023. PMID: 37076739 Free PMC article.
Procedural safety and efficacy were characterized by intra- and post-procedural complications. Acute procedural success and the long-term outcome were assessed in the overall group and in the subgroups. ...
Procedural safety and efficacy were characterized by intra- and post-procedural complications. Acute procedural success and the long-term …
COVID-19 Vaccine Booster Hesitancy in Malaysia: A Web-Based Cross-Sectional Study.
Lee KW, Yap SF, Ong HT, Oo M, Swe KMM. Lee KW, et al. Among authors: yap sf. Vaccines (Basel). 2023 Mar 13;11(3):638. doi: 10.3390/vaccines11030638. Vaccines (Basel). 2023. PMID: 36992222 Free PMC article.
The predictors of second-booster hesitancy were older age (AOR = 1.040, 95 CI = 1.022, 1.058), having received the third dose (first booster) because of instruction by the government (AOR = 2.125, 95% CI = 1.380, 3.274), concern about serious long term side effects of the …
The predictors of second-booster hesitancy were older age (AOR = 1.040, 95 CI = 1.022, 1.058), having received the third dose (first booster …
NL-EVDR: Netherlands-ExtraVascular Device Registry.
Tjong FVY, Breeman KTN, Boersma LVA, Yap SC, van Erven L, van der Stoel MD, van Dijk VF, Maass AH, Knops RE; NL-EVDR Working Group and NHR Device Registration Committee. Tjong FVY, et al. Among authors: yap sc. Neth Heart J. 2023 May;31(5):181-184. doi: 10.1007/s12471-023-01768-1. Epub 2023 Mar 2. Neth Heart J. 2023. PMID: 36862338 Free PMC article. Review.
However, it is difficult to evaluate EVDs in large studies because of high costs, lack of long-term follow-up, imprecise data or selected patient populations. To improve evaluation of these technologies, real-world, large-scale, long-term data are of utmost importan …
However, it is difficult to evaluate EVDs in large studies because of high costs, lack of long-term follow-up, imprecise data or sele …
Acute procedural efficacy and safety of a novel cryoballoon for the treatment of paroxysmal atrial fibrillation: Results from the POLAR ICE study.
Martin CA, Tilz RRR, Anic A, Defaye P, Luik A, de Asmundis C, Champ-Rigot L, Iacopino S, Sommer P, Albrecht EM, Raybuck JD, Richards E, Cielen N, Yap SC; POLAR ICE Investigators. Martin CA, et al. Among authors: yap sc. J Cardiovasc Electrophysiol. 2023 Apr;34(4):833-840. doi: 10.1111/jce.15861. Epub 2023 Feb 23. J Cardiovasc Electrophysiol. 2023. PMID: 36786515
These data are comparable to prior POLARx reports and in keeping with reported data on other cryoballoons. Future studies should examine the long-term outcomes and the relationship between biophysical parameters and outcomes for this novel cryoballoon....
These data are comparable to prior POLARx reports and in keeping with reported data on other cryoballoons. Future studies should examine the …
Alternate Cervical Venous Access Sites for Implantable Port Catheters: Experience at a Single Quaternary Care Institution.
Liou FK, Kim PY, Yap SP, Khan A, Taylor S, Pillai R, King E, Shah A, Andrews RT, Vu CT, Goldman RE. Liou FK, et al. Among authors: yap sp. Cardiovasc Intervent Radiol. 2023 Jan;46(1):43-48. doi: 10.1007/s00270-022-03306-9. Epub 2022 Dec 12. Cardiovasc Intervent Radiol. 2023. PMID: 36509940 Free PMC article.
INTRODUCTION: Clinical outcomes of implantable port catheters (IPCs) placed via alternative veins such as the external jugular and cervical collaterals have not been well established. This investigation evaluates the short- and long-term outcomes of IPCs inserted via alter …
INTRODUCTION: Clinical outcomes of implantable port catheters (IPCs) placed via alternative veins such as the external jugular and cervical …
74 results